Trial | NCT00980694  Report issue

Official Title

Bioavailability of Ubiquinol in Huntington Disease

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ubiquinol ...

  • Study Participants

    6
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.
Study Started
Sep 30
2009
Primary Completion
Jul 31
2012
Study Completion
Jul 31
2012
Last Update
May 27
2016
Estimate

Dietary Supplement ubiquinol

up to 600 mg per day, oral capsules for 8 weeks

Ubiquinol Experimental

up to 600 mg per day, oral capsules for 8 weeks

Criteria 

Inclusion Criteria:

Have manifest Huntington disease
Be 18 years of age or older
Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion Criteria:

Have a history of intolerability of sensitivity to CoQ
Have an unstable medical or psychiatric illness
Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
No Results Posted